A cervical cancer control strategy for lower-resource settings: interventions to complement one-dose HPV vaccination
Authors:
Open Access
- 1 October 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Monographs
- Vol. 2024 (67) , 417-423
Abstract
One-dose prophylactic HPV vaccination of pre-adolescents may reduce cervical cancer deaths dramatically in lower-resource settings, but the benefits of achieving immediate high coverage among pre-adolescents would not be realized for 20 to 40 years. Prophylactic vaccine efficacy is reduced after sexual debut, and current therapeutic intervention candidates designed to treat existing HPV infections or precancerous lesions have yielded insufficient evidence to warrant widespread use. However, we are developing a feasible, scalable, high-quality cervical screening approach that could prevent hundreds of thousands of deaths, while we work to achieve high coverage of one-dose vaccination for adolescent cohorts. A time-limited “one screen” campaign approach for lower-resource settings could complement parallel efforts to achieve high coverage with one-dose vaccination. This screen-triage-treat strategy would target the highest risk groups of screening age (ie, 25 to 49 years) for once-in-a-lifetime HPV testing of self-collected samples using a low-cost accurate HPV test; subsequent triage relying on extended genotyping and a validated deep-learning algorithm for automated visual evaluation (AVE) would stratify management based on risk to provide treatment for those most likely to develop cancer without overburdening health care systems. Early efficacy of this approach has been demonstrated in 9 countries within the HPV-AVE (PAVE) Study Consortium. We estimate that the cost per death averted of a screen-triage-treat campaign is of similar magnitude to prophylactic vaccination. We do not envision perpetual investment in ubiquitous brick-and-mortar screening programs if “one dose, one screen” is implemented with high coverage and targets the highest-risk populations. In collaboration with in-country stakeholders, efforts to ensure acceptability, risk communication, and cost-effectiveness are underway.Keywords
Funding Information
- National Cancer Institute Intramural Research Program
- Cancer Cures Moonshot Initiative: Accelerated Control of Cervical Cancer
- NIH
This publication has 31 references indexed in Scilit:
- Internal validation of Automated Visual Evaluation (AVE) on smartphone images for cervical cancer screening in a prospective study in ZambiaCancer Medicine, 2024
- Artificial intelligence for cervical cancer screening: Scoping review, 2009–2022International Journal of Gynecology & Obstetrics, 2023
- A rapid HPV typing assay to support global cervical cancer screening and risk‐based management: A cross‐sectional studyInternational Journal of Cancer, 2023
- Use of risk-based cervical screening programs in resource-limited settingsCancer Epidemiology, 2023
- Redesign of a rapid, low‐cost HPV typing assay to support risk‐based cervical screening and managementInternational Journal of Cancer, 2022
- The development of “automated visual evaluation” for cervical cancer screening: The promise and challenges in adapting deep‐learning for clinical testingInternational Journal of Cancer, 2021
- Potential effectiveness of a therapeutic HPV intervention campaign in UgandaInternational Journal of Cancer, 2021
- Topical therapies for the treatment of cervical intraepithelial neoplasia (CIN) 2–3: A narrative reviewGynecologic Oncology Reports, 2020
- The health and economic impact of scaling cervical cancer prevention in 50 low‐ and lower‐middle‐income countriesInternational Journal of Gynecology & Obstetrics, 2017
- HPV prevalence in women attending cervical screening in rural Malawi using the cartridge-based Xpert® HPV assayJournal of Clinical Virology, 2017